RemeGenix is developing MoBA; a disease modifying drug to treat Alzheimer's disease.
MoBA has one of the best possible safety and efficacy profile, among all of the drug candidates currently in development.
The Company's therapeutic and platform technologies were developed from a comprehensive understanding of the relationship
between a protein named BRI2 and Amyloid Precursor Protein (APP).
BRI2 was found, by Dr. D'Adamio, to be the natural binding partner of APP, and is responsible for protecting
APP from being cleaved (cut into smaller pieces) by a variety of different proteins/secretases including the beta and gamma secretases.
Importantly, individuals who have a lack of functional BRI2 have been found to have significant cognitive deficits,
and similarly the mice Dr. D'Adamio created, the basis for our NoMAD platform technology, demonstrated the same
cognitive deficits that are also associated with Alzheimer's disease.
Recovery of this cognitive decline was observed in all of the following scenarios:
Increasing the levels of BRI2 in models of dementia
Decreasing the levels of APP in our NoMAD models
Administering MoBA in models of dementia
This proof of concept data is the basis for the further pre-clinical and clinical development of RemeGenix lead candidates.
RemeGenix technology has several competitive advantages over current solutions:
Our MoBA pipeline represents a new therapeutic approach that has been shown to specifically modulate
beta secretase access to APP, for example limiting the production of byproducts of APP such as:
- sAPPBeta, and others
The mechanism of action of our pipeline is specific and is less likely to inhibit normal,
ongoing biological processes. Current alternatives focusing on divergent pathways will more likely have
side effects when administered to patients, and have shown such side effects in recent clinical trials.
RemeGenix' technology has the potential to compete on a cost and efficacy basis with other products in this disease space.
RemeGenix' technology is potentially applicable to multiple types of dementia and cognitive disorders.
RemeGenix' approach has been validated in animal models of disease as well as a human disease.